Sun Pharma Swears By Time-tested U.S., India Markets As It Builds Specialty Business
This article was originally published in PharmAsia News
India’s Sun Pharma has beaten street expectations in recent years, and as the business now inches beyond the $2 billion sales mark, largely from the United States, Sun’s challenges are becoming more complex. Founder Dilip Shanghvi sat down with PharmAsia News for an exclusive interview to discuss the company’s future.
You may also be interested in...
The high court says the Hatch-Waxman Act did not intend for one patented use of a drug to prevent the marketing of a generic for unpatented uses; Justice Sotomayor criticizes FDA for not providing clearer direction to brand manufacturers about what to include in their use codes.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.